NEUROG3 Is Sufficient to Drive Neuroendocrine Differentiation in Prostate Cancer Cells

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Treatment-emergent neuroendocrine prostate cancer (t-NEPC) develops after androgen deprivation therapy, promoting aggressive, androgen-independent growth.
• While factors for neuroendocrine differentiation (NED) are known, their sufficiency in driving t-NEPC remains unproven.
• Prostate and colorectal tissues share developmental origins, with overlapping cell markers suggesting a potential shared regulatory pathway.

Purpose of the Study:

• To investigate the role of Neurogenin-3 (NEUROG3) in driving neuroendocrine differentiation (NED) in prostate cancer cells.
• To determine if NEUROG3 is sufficient to induce NED, mirroring its known function in colorectal enteroendocrine cell differentiation.
• To establish a rapid in vitro model for studying NEUROG3-mediated prostate cancer progression.

Main Methods:

• Analysis of patient datasets to identify NEUROG3 amplification in castration-resistant and neuroendocrine prostate cancers.
• In vitro experiments involving transient NEUROG3 activation in prostate cancer cells.
• Assessment of cellular identity changes and neuroendocrine program activation following NEUROG3 induction.

Main Results:

• NEUROG3 amplification was found to correlate with poor survival in prostate cancer patients.
• A transient pulse of NEUROG3 expression was sufficient to repress luminal cell identity.
• NEUROG3 activation rapidly induced neuroendocrine programs, generating neuroendocrine cells within seven days.

Conclusions:

• NEUROG3 acts as a potential mediator in the progression of prostate cancer towards a neuroendocrine phenotype.
• The study establishes a novel and rapid in vitro model demonstrating the sufficiency of transient NEUROG3 activation in initiating prostate cancer neuroendocrine differentiation.